Skip to content
The Kids Research Institute Australia logo
Donate

Search

Interleukin-1 is associated with inflammation and structural lung disease in young children with cystic fibrosis

Interleukin-1 is associated with inflammation and structural lung disease in young children with cystic fibrosis Early diagnosis and treatment in

The association between Staphylococcus aureus and subsequent bronchiectasis in children with cystic fibrosis

The association between Staphylococcus aureus and subsequent bronchiectasis in children with cystic fibrosis Abstract Background: Staphylococcus

Clinical utility of surveillance computed tomography scans in infants with cystic fibrosis

Clinical utility of surveillance computed tomography scans in infants with cystic fibrosis Abstract Background: In cystic fibrosis (CF), irreversible

Elastase exocytosis by airway neutrophils is associated with early lung damage in children with cystic fibrosis.

Elastase exocytosis by airway neutrophils is associated with early lung damage in children with cystic fibrosis Abstact Rationale: Neutrophils are

Single-breath washout and association with structural lung disease in children with cystic fibrosis

Single-breath washout and association with structural lungdisease in children with cystic fibrosis Abstract Background: In children with cystic

Multiple Breath Washout Outcomes Are Sensitive to Inflammation and Infection in Children with Cystic Fibrosis

Multiple Breath Washout Outcomes Are Sensitive to Inflammation and Infection in Children with Cystic Fibrosis The multiple breath washout technique

Effect of Posture on Lung Ventilation distribution and Associations with Structure in Children with Cystic Fibrosis

Effect of Posture on Lung Ventilation distribution and Associations with Structure in Children with Cystic Fibrosis Effect of Posture on Lung

MRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis

A The Kids Research Institute Australia spin-off company has received $20 million from the Medical Research Commercialisation Fund to develop a promising new therapy for the treatment of Cystic Fibrosis.